AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.05
+1.01 (+2.80%)
As of 10:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.04
Open36.01
Bid36.99 x 1200
Ask37.12 x 1000
Day's Range35.80 - 37.17
52 Week Range33.17 - 79.17
Volume82,174
Avg. Volume568,023
Market Cap2.149B
Beta (3Y Monthly)2.26
PE Ratio (TTM)N/A
EPS (TTM)-6.67
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est74.67
Trade prices are not sourced from all markets
  • GlobeNewswire

    Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the Phase 3 ClarIDHy study of TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma have been accepted for presentation in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Annual Meeting being held September 27 – October 1, 2019 in Barcelona. Agios will host a conference call and live webcast with presentation slides on September 30, 2019 at 1 p.m. ET /7 p.m. CET to discuss the data from the ClarIDHy study. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology.

  • Thomson Reuters StreetEvents

    Edited Transcript of AGIO earnings conference call or presentation 1-Aug-19 12:00pm GMT

    Q2 2019 Agios Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that new data from the core and extension phases of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency were published in the September 5, 2019 issue of the New England Journal of Medicine. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes that directly targets the underlying metabolic defect in PK deficiency, a rare, potentially debilitating, hemolytic anemia.

  • Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound?
    Zacks

    Agios Pharmaceuticals (AGIO) Down 11.2% Since Last Earnings Report: Can It Rebound?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Citi 14th Annual Biotech Conference in Boston on Thursday, September 5, 2019 at 12:00 p.m. ET. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.

  • Agios Rides High on Tibsovo Sales Amid Acute Competition
    Zacks

    Agios Rides High on Tibsovo Sales Amid Acute Competition

    Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.

  • An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 50% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Suggests It's 50% Undervalued

    How far off is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from its intrinsic value? Using the most recent financial...

  • Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript

    AGIO earnings call for the period ending June 30, 2019.

  • Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales
    Zacks

    Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

    Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

  • Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -8.09% and 6.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Agios Reports Business Highlights and Second Quarter 2019 Financial Results

    Strong Topline Performance for IDH Inhibitors: TIBSOVO® Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA® Royalty Increased to $2.7M Achieved Important Expansion.

  • Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

    Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 1, 2019 at 8:00 a.m. ET to report its second quarter 2019 financial results and other business highlights. A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology.

  • Markit

    See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

    Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AGIO is favorable, with net inflows of $5.05 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire

    Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Orlando Oliveira to the role of senior vice president and general manager, international, who will be responsible for building and leading the company’s operations outside of the U.S. in support of the expected launch of TIBSOVO® in Europe and potentially other select markets. Mr. Oliveira will be based in Zug, Switzerland and report to Jackie Fouse, Ph.D., chief executive officer at Agios.

  • Agios (AGIO) Catches Eye: Stock Jumps 5.4%
    Zacks

    Agios (AGIO) Catches Eye: Stock Jumps 5.4%

    Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?
    Simply Wall St.

    Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?

    Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

  • Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]

  • GlobeNewswire

    Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 11, 2019 at 2:40 p.m. PT. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.

  • Life sciences VC firm Third Rock raises $770M in its largest round ever
    American City Business Journals

    Life sciences VC firm Third Rock raises $770M in its largest round ever

    One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.

  • GlobeNewswire

    Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the planned retirement of its chief scientific officer, Scott Biller, Ph.D. Dr. Biller will retire from his CSO position at the end of 2019 and continue to serve as a strategic advisor through the end of 2020. Under his leadership, the team has built a robust preclinical pipeline and advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage clinical programs,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “It has been a privilege and honor to be a part of the Agios team for nearly a decade and to work toward our shared vision of making a meaningful impact on the lives of patients,” said Dr. Biller.